Contrasting responses to interferon β-1b treatment in relapsing-remitting multiple sclerosis: Does baseline interleukin- 12p35 messenger RNA predict the efficacy of treatment?

Annals of Neurology

Volumn 48, Issue 3, 2000, Pages 313-322

  Van Boxel Dezaire, A H H ^a,b   Van Trigt Hoff, S C J ^a   Killestein, J ^b   Schrijver, H M ^b   Van Houwelingen, J C ^a   Polman, C H ^b   Nagelkerken, L ^a,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 18; MESSENGER RNA; PROTEIN P35; PROTEIN P40;

ADULT; ARTICLE; CLINICAL ARTICLE; DISABILITY; DISEASE CLASSIFICATION; DNA SYNTHESIS; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HUMAN; MALE; MULTIPLE SCLEROSIS; PREDICTION; PRIORITY JOURNAL; RATING SCALE; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; FEMALE; HUMANS; INTERFERON-BETA; INTERLEUKIN-12; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDICTIVE VALUE OF TESTS; RNA, MESSENGER; TIME FACTORS;

EID: 0033849496     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(200009)48:3<313::AID-ANA5>3.0.CO;2-9     Document Type: Article

References (33)

1. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
2. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group
3. Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis
4. Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells
5. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta
6. Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer
7. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis
8. Influence of IFN-beta1b (Betaferon) on cytokine mRNA profiles in blood mononuclear cells and plasma levels of soluble VCAM-1 in multiple sclerosis
9. Antagonism of interferon beta on interferon gamma: Inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients
10. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b
11. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: Correlation with disease phase and interferon-beta therapy
12. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis
13. T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes
14. Evolution of the T-cell repertoire during the course of experimental immunemediated demyelinating diseases
15. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis
16. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases
17. Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis
18. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients
19. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
20. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy
21. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis
22. IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes
23. Selective expression of an interleukin-12 receptor component by human T helper 1 cells
24. Standardization of mRNA titration using a polymerase chain reaction method involving co-amplification with a multispecific internal control
25. Differential regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids in vitro
26. An interleukin (IL)-10/ IL-12 immunoregulatory circuit controls susceptibility to auto-immune disease
27. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients
28. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
29. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
30. Interferon beta induces interleukin-10 expression: Relevance to multiple sclerosis
31. Blood levels of transforming growth factor-beta 1 (TGF-beta 1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b)
32. Transforming growth factor beta 1: Importance of glycosylation and acidic proteases for processing and secretion
33. Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit